ERBB2 and breast neoplasm: These statistics complement data in a recent molecular analysis of breast tumors in a Nigerian population, in whom 68% of tumors tested were ER negative, 25% were HER2 positive, and ER-positive tumors were biologically more aggressive.15 In the United States, subtype prevalence is notably different (33% vs ~20% ER negative; 17% vs ~15% HER2 positive for black and white, respectively).16 This significant difference in subtype prevalence and aggressiveness of cancer in African populations illustrates the need to know biomarker status for treatment.